Risk Factors for Xerostomia Following Radiotherapy of Head-and-Neck Cancers

Area of Science:

• Oncology
• Radiation Oncology
• Head and Neck Cancer Research

Background:

• Radiotherapy for head and neck cancers can cause significant toxicities.
• Xerostomia (dry mouth) is a common and debilitating late adverse effect of this treatment.
• Identifying risk factors for xerostomia is crucial for patient management.

Purpose of the Study:

• To identify risk factors associated with the development of late xerostomia in patients treated with radiotherapy for head and neck cancer.

Main Methods:

• A cohort of 159 patients undergoing radiotherapy for head and neck cancer was analyzed.
• Investigated factors included patient demographics, tumor characteristics, and treatment details (radiotherapy type/dose, systemic therapy).
• Statistical analysis was performed to determine associations with xerostomia severity (Grade ≥2 and Grade ≥3).

Main Results:

• 57% of patients experienced Grade ≥2 xerostomia, and 22% experienced Grade ≥3 xerostomia.
• Grade ≥2 xerostomia was significantly linked to specific tumor sites (nasopharynx, oropharynx, oral cavity, floor of mouth).
• Grade ≥3 xerostomia showed significant association with older age (≥61 years) and trends with tumor site, bilateral nodal involvement, definitive treatment, and systemic therapy.

Conclusions:

• Older age, unfavorable tumor site, bilateral lymph node involvement, definitive treatment, and systemic therapies are identified risk factors for xerostomia.
• Salivary gland sparing is particularly important for patients with identified risk factors.
• These findings aid in personalized treatment strategies to mitigate xerostomia in head and neck cancer patients.